PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35330134-3	2022	In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan.	Carboplatin	159-170	ATP binding cassette subfamily B member 1	Homo sapiens	149-153	
35330134-6	2022	Paclitaxel has shown the highest binding affinity whereas Carboplatin displayed the lowest affinity to MRP1.	Carboplatin	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	103-107	
35330134-7	2022	Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1.	Carboplatin	36-47	ATP binding cassette subfamily B member 1	Homo sapiens	149-153	
35330134-8	2022	Our results suggest that Carboplatin could be an appropriate therapeutic choice against MRP1 in OC as it couples weakly with Carboplatin.	Carboplatin	125-136	ATP binding cassette subfamily B member 1	Homo sapiens	88-92